735 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Ultragenyx to Submit sBLA for Label Expansion of Crysvita http://www.zacks.com/stock/news/513339/ultragenyx-to-submit-sbla-for-label-expansion-of-crysvita?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-513339 Sep 11, 2019 - Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus http://www.zacks.com/stock/news/513224/biotech-stock-roundup-amgns-lung-cancer-candidate-alxns-deal-with-eidos-in-focus?cid=CS-ZC-FT-analyst_blog|stock_roundup-513224 Sep 11, 2019 - Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy http://www.zacks.com/stock/news/511106/adaptimmune-adap-gets-orphan-drug-status-for-t-cell-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-511106 Sep 10, 2019 - Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review http://www.zacks.com/stock/news/510923/horizons-hznp-eye-disease-drug-gets-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-510923 Sep 10, 2019 - Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Company News For Sep 10, 2019 http://www.zacks.com/stock/news/511059/company-news-for-sep-10-2019?cid=CS-ZC--corporate_summary-511059 Sep 10, 2019 - Companies In The News Are: T,AA,AMGN,BA
Amgen (AMGN) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow https://seekingalpha.com/article/4290609-amgen-amgn-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=feed_sector_healthcare Sep 09, 2019 - The following slide deck was published by Amgen Inc. in conjunction with this event.
Novartis Announces Positive Long-Term Data on Migraine Drug http://www.zacks.com/stock/news/509529/novartis-announces-positive-long-term-data-on-migraine-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509529 Sep 09, 2019 - Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy https://www.fool.com/investing/2019/09/06/why-amgens-spending-billions-to-buy-this-1-drug-pl.aspx?source=iedfolrf0000001 Sep 06, 2019 - Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
4 Biotech Stocks With Big Catalysts in September https://www.fool.com/investing/2019/09/05/biotech-stocks-with-big-catalysts-in-september.aspx?source=iedfolrf0000001 Sep 05, 2019 - Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer http://www.zacks.com/stock/news/503040/mercks-keytruda-combination-gets-ec-nod-for-kidney-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503040 Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.

Pages: 123456789...74

<<<Page 4>